Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) Shorts Rose By 0.91% As Of Apr 7, 2019

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Corporate Logo

Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) had an increase of its shorted shares by 0.91%. FINRA announced shorted shares of LXRX’s total 8.00 million shares. Previously was reported up change of 0.91% from 7.93M shares. Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) has 537,100 shares average volume. It’ll cost 15 days for LXRX to restore its former position. 7.58% is Lexicon Pharmaceuticals Inc float short.

Ticker’s shares touched $6.22 during the last trading session after 2.47% change.Currently Lexicon Pharmaceuticals, Inc. is downtrending after 20.39% change in last April 7, 2018. LXRX has 772,761 shares volume. LXRX underperformed by 24.76% the S&P500.

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products for the treatment of human diseases.The company has $661.01 million market cap. The firm offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with SSA therapy in adults.Currently it has negative earnings. The Company’s orally-delivered small molecule drug candidates under development comprise Sotagliflozin that is in Phase 3 clinical trials for use in the treatment of type 1 and type 2 diabetes; LX2761, which is in Phase 1 development for use in the treatment of diabetes; and LX9211 for use as a treatment for neuropathic pain.

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Ratings Coverage

In total 3 analysts cover Lexicon Pharmaceuticals (NASDAQ:LXRX). “Buy” rating has 3, “Sell” are 0, while 0 are “Hold”. (NASDAQ:LXRX) has 100% bullish analysts. 10 are the (NASDAQ:LXRX)’s ratings reports on Apr 7, 2019 according to StockzIntelligence Inc. On Friday, March 15 the rating was maintained by Wedbush with “Buy”. On Friday, November 2 the stock has “Buy” rating by Citigroup. On Monday, March 4 the stock of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) has “Buy” rating given by Wedbush. On Thursday, March 14 the rating was downgraded by Gabelli to “Sell”. On Monday, March 25 the firm earned “Buy” rating by Wedbush. On Monday, March 25 the stock of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) earned “Buy” rating by Stifel Nicolaus.

For more Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) news announced briefly go to: Globenewswire.com, Nasdaq.com, Benzinga.com, Benzinga.com or Benzinga.com. The titles are as follows: “CLASS ACTION UPDATE for LXRX, BRS, WTW and AMR: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders – GlobeNewswire” announced on April 01, 2019, “Lexicon Pharma Initiates Dosing in Biliary Tract Cancer Study – Nasdaq” on March 18, 2019, “48 Stocks Moving In Wednesday’s Mid-Day Session – Benzinga” with a publish date: March 13, 2019, “Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings (March 17-23) – Benzinga” and the last “52 Biggest Movers From Yesterday – Benzinga” with publication date: March 26, 2019.

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.